Yin, Wesley - In: Journal of Health Economics 27 (2008) 4, pp. 1060-1077
I study the impact of the Orphan Drug Act (ODA), which established tax incentives for rare disease drug development. I examine the flow of new clinical drug trials for a large set of rare diseases. Among more prevalent rare diseases, the ODA led to a significant and sustained increase in new...